Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key step in Continuity’s strategy to become a leader in device targeted therapeutics for intractable solid tumors. Founded by leading scientists and clinicians, Focal Medical has developed a proprietary platform that delivers chemotherapy directly to tumors using iontophoresis—this minimally-invasive technique utilizes a mild electrical current to drive therapeutic compounds into targeted tissues.
Read the full article: Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer //
Source: https://www.prnewswire.com/news-releases/continuity-biosciences-acquires-focal-medical-to-advance-targeted-drug-delivery-for-pancreatic-cancer-302472112.html